Drug Profile
Research programme: second-generation HIV viral entry inhibitors - TaiMed Biologics
Alternative Names: TMB-358Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator TaiMed Biologics
- Class Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-1-infections in USA
- 27 Jun 2011 Preclinical trials in HIV-1 infections in USA (unspecified route)